<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00516243</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00858</org_study_id>
    <secondary_id>NCI-2009-00858</secondary_id>
    <secondary_id>IRB-AAAB7638</secondary_id>
    <secondary_id>CDR0000653465</secondary_id>
    <secondary_id>2006-0521</secondary_id>
    <secondary_id>MDA04-4-01</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <secondary_id>N01CN35159</secondary_id>
    <nct_id>NCT00516243</nct_id>
  </id_info>
  <brief_title>Defined Green Tea Catechin Extract in Treating Women With Hormone Receptor Negative Stage I-III Breast Cancer</brief_title>
  <official_title>Phase IB Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Women With a History of Hormone Receptor-Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase I trial studies the side effects and best dose of defined green tea&#xD;
      catechin extract in treating women with hormone receptor-negative stage I-III breast cancer.&#xD;
      Green tea extract contains ingredients that may prevent or slow the growth of breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Demonstrate the safety of green tea catechin extract (Polyphenon E) in women with a&#xD;
      history of hormone receptor-negative breast cancer.&#xD;
&#xD;
      II. Determine the maximum tolerated dose of Polyphenon E in women with a history of hormone&#xD;
      receptor-negative breast cancer.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the efficacy of Polyphenon E in modulating histologic changes (nonproliferative,&#xD;
      proliferative without atypia, atypical hyperplasia) on core biopsy of the contralateral&#xD;
      breast.&#xD;
&#xD;
      II. Determine the efficacy of Polyphenon E in modulating immunohistochemical expression of&#xD;
      Ki-67 (proliferation index), p53, EGFR, HER2/neu, cleaved caspase-3 (apoptosis marker), and&#xD;
      estrogen receptor on core biopsy tissue of the contralateral breast.&#xD;
&#xD;
      III. Determine the efficacy of Polyphenon E in modulating mammographic breast density of the&#xD;
      contralateral breast.&#xD;
&#xD;
      IV. Determine the efficacy of Polyphenon E in modulating hormone metabolites (serum&#xD;
      estradiol, testosterone, IGF-1, IGFBP-3, SHBG).&#xD;
&#xD;
      V. Determine the efficacy of Polyphenon E in modulating eicosanoid levels (urine PGE-M).&#xD;
&#xD;
      VI. Determine the efficacy of Polyphenon E in modulating biomarkers of oxidative damage&#xD;
      (urine 8-OHdG, isoprostane).&#xD;
&#xD;
      VII. Determine the efficacy of Polyphenon E in modulating serum C-reactive protein.&#xD;
&#xD;
      VIII. Determine the activity of Polyphenon E in relation to COMT genotype. IX. Assess quality&#xD;
      of life and attitudes toward complementary and alternative medicine in women with a history&#xD;
      of breast cancer.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study. Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
      ARM I: Patients receive defined green tea catechin extract orally (PO) twice daily (BID) for&#xD;
      6 months in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      ARM II: Patients receive placebo PO BID for 6 months in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Patients undergo a core biopsy and mammogram of the contralateral breast at baseline and&#xD;
      after 6 months for histological evaluation, IHC analysis, and mammographic density reading.&#xD;
      Core biopsy tissue is assessed for proliferative changes and presence of atypia using&#xD;
      standardized histological criteria. Core biopsy tissue is also analyzed by IHC for the&#xD;
      following proteins: Ki-67 (proliferation index), p53, EGFR, HER2/neu, cleaved caspase-3&#xD;
      (apoptosis marker), and estrogen receptor (ER). Blood and urine samples are collected at&#xD;
      baseline and every 2 months during treatment to measure drug effect biomarkers: serum&#xD;
      estradiol, testosterone, insulin-like growth factor-1 (IGF-1), IGF binding protein-3&#xD;
      (IGFBP-3), and sex hormone-binding globulin (SHBG) by immunological laboratory methods; urine&#xD;
      prostaglandin levels (PGE-M) by tandem mass spectrometry; urine oxidative damage markers&#xD;
      (8-OHdG, isoprostane) and serum C-reactive protein (CRP) by ELISA; and&#xD;
      catechol-O-methyltransferase (COMT) genotype (at baseline only).&#xD;
&#xD;
      Patients complete a questionnaire assessing quality of life (SF-36) and attitudes toward&#xD;
      complementary and alternative medicine at baseline and at 6 months.&#xD;
&#xD;
      After completion of study treatment, patients are followed for 1 month.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD defined as the dose that causes 25% DLT assessed using NCI CTCAE version 3.0</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Breast tissue histology (nonproliferative, proliferative without atypia, atypical hyperplasia)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Generalized linear models will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COMT genotype</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Generalized linear models will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality-of-life measures assessed using SF-36</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Generalized linear models will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protein expression levels in benign breast tissue (Ki-67, p53, EGFR, HER2/neu, cleaved caspase-3, and ER)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Generalized linear models will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative mammographic breast density</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Generalized linear models will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hormone metabolite levels (estradiol, testosterone, IGF-1, IGFBP-3, SHBG)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Generalized linear models will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eicosanoid levels (urine PGE-M)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Generalized linear models will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of oxidative damage biomarkers (urine 8-OHdG, isoprostane)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Generalized linear models will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum CRP levels</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Generalized linear models will be used.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Estrogen Receptor-negative Breast Cancer</condition>
  <condition>Progesterone Receptor-negative Breast Cancer</condition>
  <condition>Stage I Breast Cancer</condition>
  <condition>Stage II Breast Cancer</condition>
  <condition>Stage IIIA Breast Cancer</condition>
  <condition>Stage IIIB Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I (defined green tea catechin extract)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive defined green tea catechin extract PO BID for 6 months in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive placebo PO BID for 6 months in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <other_name>PLCB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (defined green tea catechin extract)</arm_group_label>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <other_name>quality of life assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>questionnaire administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (defined green tea catechin extract)</arm_group_label>
    <arm_group_label>Arm II (placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (defined green tea catechin extract)</arm_group_label>
    <arm_group_label>Arm II (placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>defined green tea catechin extract</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (defined green tea catechin extract)</arm_group_label>
    <other_name>Polyphenon E</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Criteria:&#xD;
&#xD;
          -  History of histologically confirmed stage I, II, or III breast carcinoma without&#xD;
             evidence of disease at study entry&#xD;
&#xD;
          -  No evidence of recurrent disease (patients with resected local recurrence are&#xD;
             eligible)&#xD;
&#xD;
          -  Normal mammogram of the contralateral breast within the past 12 months, defined as no&#xD;
             new suspicious calcifications or other abnormal findings warranting a breast biopsy&#xD;
&#xD;
          -  No history of histologically confirmed bilateral breast cancer&#xD;
&#xD;
          -  No evidence of metastatic breast cancer&#xD;
&#xD;
          -  Registered in the outpatient medical oncology clinic at Columbia University Medical&#xD;
             Center (CUMC), MD Anderson Cancer Center (MDACC), Memorial Sloan Kettering Cancer&#xD;
             Center (MSKCC), or the Weill-Cornell campus of New York Presbyterian Hospital (NYP-WC)&#xD;
&#xD;
          -  Hormone receptor status: Estrogen- and progesterone-receptor negative&#xD;
&#xD;
          -  Menopausal status: Pre- or postmenopausal&#xD;
&#xD;
          -  ECOG performance status &lt; 2 (Karnofsky &gt; 60%)&#xD;
&#xD;
          -  Leukocytes &gt;= 3,000/uL&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1,500/uL&#xD;
&#xD;
          -  Platelets &gt;= 100,000/uL&#xD;
&#xD;
          -  Total bilirubin within normal institutional limits&#xD;
&#xD;
          -  AST/ALT =&lt; 2.5 times institutional upper limit of normal&#xD;
&#xD;
          -  Serum creatinine within normal institutional limits&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Women of child-bearing potential must agree to use adequate contraception (hormonal or&#xD;
             barrier method of birth control; abstinence) prior to study entry and for the duration&#xD;
             of study participation&#xD;
&#xD;
          -  No history of allergic reactions attributed to compounds of similar chemical or&#xD;
             biologic composition to green tea extract (Polyphenon E), such as green tea food&#xD;
             products or supplements containing EGCG&#xD;
&#xD;
          -  No history of gastrointestinal bleeding including, but not limited to, any of the&#xD;
             following: Diverticulosis; Peptic ulcer disease; Erosive gastritis; Varices&#xD;
&#xD;
          -  No uncontrolled or significant co-morbid illness including, but not limited to, any of&#xD;
             the following: active or serious infection requiring intravenous antibiotics;&#xD;
             symptomatic congestive heart failure; unstable angina pectoris; cardiac arrhythmia;&#xD;
             active gastrointestinal bleeding; active liver disease; psychiatric illness/social&#xD;
             situations that would limit compliance with study requirements&#xD;
&#xD;
          -  No active malignancy, except for squamous cell carcinoma of the skin; basal cell&#xD;
             carcinoma of the skin; carcinoma in situ; stage IA or IB invasive squamous cell&#xD;
             carcinoma of the cervix treated by surgery and/or radiation therapy; or stage IA grade&#xD;
             1 adenocarcinoma of the endometrium treated by surgery&#xD;
&#xD;
          -  At least 6 months since prior chemotherapy, radiation therapy, and/or breast surgery&#xD;
&#xD;
          -  No prior radiation therapy or implant in the contralateral breast&#xD;
&#xD;
          -  More than 30 days since prior and no concurrent medications, herbs, or vitamin and&#xD;
             mineral supplements that contain tea compounds or caffeine&#xD;
&#xD;
          -  At least 30 days since prior and no other concurrent investigational agents&#xD;
&#xD;
          -  At least 30 days since prior and no concurrent tea consumption&#xD;
&#xD;
          -  Willing to limit regular coffee consumption to =&lt; three 8-ounce cups per day for 30&#xD;
             days prior to baseline evaluation and during the study intervention&#xD;
&#xD;
          -  Total daily caffeine consumption should not exceed 375 mg/day&#xD;
&#xD;
          -  No concurrent hormone replacement therapy, tamoxifen, or raloxifene&#xD;
&#xD;
          -  Concurrent oral contraceptives allowed provided the dose has not been changed for at&#xD;
             least 6 months prior to study entry&#xD;
&#xD;
          -  No concurrent chemotherapy or radiation therapy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dawn Hershman</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <study_first_submitted>August 14, 2007</study_first_submitted>
  <study_first_submitted_qc>August 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2007</study_first_posted>
  <last_update_submitted>September 11, 2014</last_update_submitted>
  <last_update_submitted_qc>September 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epigallocatechin gallate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

